Andrew Cormack

Andrew Cormack currently serves as the Chief Commercial Officer at enVVeno Medical, where leadership focuses on the commercialization strategy for the VenoValve, aimed at treating severe chronic venous insufficiency. Previously, Andrew held the role of Chief Commercial Officer at phenox, overseeing North American commercial strategies for the WallabyPhenox neurovascular product portfolio. Andrew's extensive experience includes a tenure as Vice President of Global Marketing for Neurovascular at Medtronic, where leadership encompassed the global Neurovascular product portfolio strategy. Additional roles at Covidien and ev3 involved strategic marketing and development for vascular and neurovascular therapies across various international markets. Andrew is a graduate of Western University with an Honours Bachelor of Arts degree in Kinesiology and Exercise Science.